Skip to main content

Gout

gout.MTP_.jpg
Patients with refractory gout and those with high burden of tophi have only few options when it comes to uric acid lowering agents. Many of these patients have coexisting chronic kidney disease (CKD…
RT @JulianSegan: GWAS analysis of 2.5m people (120k with gout) showing identifies 1486 candidate causal genes for gout.

Julian Segan JulianSegan

3 weeks 1 day ago
GWAS analysis of 2.5m people (120k with gout) showing identifies 1486 candidate causal genes for gout. Looking at urate handling as well as disease propagation (eg. IL1/6). Widespread GWAS allowing us to investigate these diseases differently. @RheumNow #ACR22 #Plenary
RT @Janetbirdope: #ACR highlights - #pegloticase in #gout - less reactions and more benefit w #MTX MIRROR RCT. Better th

Janet Pope Janetbirdope

3 weeks 1 day ago
#ACR highlights - #pegloticase in #gout - less reactions and more benefit w #MTX MIRROR RCT. Better than no MTX. Will change my practice - if I can access to a #peguricase, I will Rx w concomitant MTX Abst#0001 #ACR22 @RheumNow
RT @RichardPAConway: Venuturupalli et al. Elevated CASPASE 1 expression in synovial biopsies of inter-critical gout sugg

Richard Conway RichardPAConway

3 weeks 1 day ago
Venuturupalli et al. Elevated CASPASE 1 expression in synovial biopsies of inter-critical gout suggest ongoing NLRP3 inflammasome activity between gout attacks. @RheumNow #ACR22 Abstr#1808 https://t.co/OnJOpkRqH9 https://t.co/TGd6pn8Lne
RT @RichardPAConway: Nair et al. HLA-B*5801 allele in African American gout patients. Present in 8%. Higher than expecte

Richard Conway RichardPAConway

3 weeks 1 day ago
Nair et al. HLA-B*5801 allele in African American gout patients. Present in 8%. Higher than expected, ?need for screening pre-allopurinol? @RheumNow #ACR22 Abstr#1793 https://t.co/KrsjQ836BY https://t.co/bmPyqQi7OF
RT @RichardPAConway: Hayashi et al. No effect of colchicine prophylaxis (vs NSAID or vs no prophylaxis) on MACE in re-an

Richard Conway RichardPAConway

3 weeks 1 day ago
Hayashi et al. No effect of colchicine prophylaxis (vs NSAID or vs no prophylaxis) on MACE in re-analysis of CARES trial. @RheumNow #ACR22 Abstr#1809 https://t.co/I6evAl4BLd https://t.co/n70FvYah1p
RT @RichardPAConway: Lin et al. Genetic risk (HR 2.3 women, 2.63 men) and lifestyle (HR 5.7 for women, 3.7 for men) both

Richard Conway RichardPAConway

3 weeks 1 day ago
Lin et al. Genetic risk (HR 2.3 women, 2.63 men) and lifestyle (HR 5.7 for women, 3.7 for men) both individual contributors and synergistic (HR 9.1 women, 8.7 men) in gout development in both men and women. Modifiable! @RheumNow #ACR22 Abstr#1633 https://t.co/51KPgfXn1w https://t.co/gOU7DfOKvt
RT @RichardPAConway: Helget et al. Subanalysis of STOP Gout. Allopurinol and febuxostat equal efficacy in CKD 3. More AK

Richard Conway RichardPAConway

3 weeks 1 day ago
Helget et al. Subanalysis of STOP Gout. Allopurinol and febuxostat equal efficacy in CKD 3. More AKI with allopurinol 8.3% vs 2.4%. @RheumNow #ACR22 Abstr#1829 https://t.co/Z4JqYp4mTT https://t.co/xd8VGJVkNo
×